- This event has passed.
In the Healthcare Industry, we often view the access challenge as incredibly difficult in order for the UK to reimburse and recommend new, innovative therapies. But how do we really perform in the most innovative Cell and Gene therapies? How does UK Pharma feel about the challenge? Does the current pace of change correlate with industry perception?
This free webinar will allow UK pharma market access colleagues to understand how the UK authorities are performing compared to the rest of Europe and discuss the confidence that their colleagues have in the UK reimbursement systems to ensure people with rare diseases don’t get left behind.
Please note, If you do not already have a PM Society account, you will need to create a free account in order to register for this event, please click here. If you already have a username and password, you do not need to create a free account. Please contact Helen if you need any assistance.
Once you have registered for a ticket to this free event you will receive an email with details on how to join the Zoom webinar nearer to the event date.
Tickets for this event are free of charge, however, if you would like to make a small donation to the PM Society’s charity, PAPYRUS, this would be gratefully received. To read more about PAPYRUS, the work they do and to make a donation, please visit our charity page.
-
4:00 pm
Introduction
Andrew Mumford, Principal Consultant – Market Access, Initiate Consultancy -
4:20 pm
The pace of reimbursement in cell and gene therapies, how is the UK performing compared to Europe
Beth English, Market Access Consultant, Initiate Consultancy -
4:45 pm
Panel Discussion – Industry reflections on the varying pace of change
Led by Craig Bradley, Head of Marketing – Diabetes & Internal Medicine, TakedaJerome Penn, Senior Public Affairs Manager, Takeda
-
5:10 pm
Q&A
Andrew Mumford, Principal Consultant – Market Access, Initiate Consultancy